Vol. 2 No. 3 (2022)
Reimbursement Reviews

Mecasermin (Increlex)

Published March 1, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses mecasermin (Increlex), 10 mg/mL (40 mg/4mL vial), sterile solution for subcutaneous injection.
  • Indication: Treatment of growth failure in children and adolescents from 2 to 18 years with confirmed SPIGFD. SPIGFD is defined by:
    • height standard deviation score ≤ −3.0
    • basal IGF-1 levels below the 2.5th percentile for age and gender
    • growth hormone sufficiency
    • exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypopituitarism, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids
  • SPIGFD includes patients with mutations in the GHR gene/Laron’s syndrome, post-GHR signalling pathway, and IGF-1 gene defects.